The findings of our results showed that temozolomide is an effective therapy for all WHO grade 4 glioma patients irrespective of their IDH mutation profile and methylated MGMT promoter is a good prognostic marker in the setting of treatment with an alkylating agent (temozolomide); and may be predictive of improved overall survival. Here, IDH1 is linked to glioma.